STOCKWATCH
·
Pharmaceuticals
Rating7 Oct 2025, 05:21 pm

Hikal Ltd Receives 'Crisil ESG 55' Rating, Outperforms Peers in Renewable Energy, Waste Recycling, and Board Diversity

AI Summary

Hikal Ltd has been assigned an ESG Rating of ‘Crisil ESG 55’ by CRISIL ESG Ratings & Analytics Limited. The company performed better than its peers on several parameters including a better mix of renewables in energy consumption, lower withdrawal of water from stressed areas, overall waste recycling, employee training on skill upgradation and safety measures, Board strength, gender diversity, attendance of independent directors at the board meeting, and a clean record of whistleblower and investor complaints in fiscal 2025. Notably, the company did not engage CRISIL ESG Ratings & Analytics Limited for this rating, which was independently prepared based on data available in the public domain.

Key Highlights

  • Hikal Ltd receives 'Crisil ESG 55' rating
  • Outperformed peers in renewable energy consumption
  • Lower withdrawal of water from stressed areas & overall waste recycling
  • Excelled in employee training on skill upgradation and safety measures
  • Strong Board with gender diversity and high attendance of independent directors
HIKAL
Pharmaceuticals
HIKAL LTD.

Price Impact